Lanean...
An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?
As the first monoclonal antibody against vascular endothelial growth factor (VEGF), bevacizumab (BEV) is a definitely controversial antiangiogenic therapy in breast cancer. The initial excitement over improvements in progression-free survival (PFS) with BEV was tempered by an absence of overall surv...
Gorde:
| Argitaratua izan da: | Chin J Cancer Res |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
AME Publishing Company
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6736652/ https://ncbi.nlm.nih.gov/pubmed/31564802 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21147/j.issn.1000-9604.2019.04.03 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|